Indolent B-cell lymphomas are heterogeneous, comprising three grades of follicular lymphoma, small lymphocytic lymphoma, Waldenst€ om macroglobulinemia, marginal zone lymphoma, and most recently, possibly low proliferative mantle cell lymphoma. These lymphomas are characterized by a high responsiveness to chemotherapy or immunochemotherapy; however, in most cases, conventional therapy might not offer a cure. Furthermore, the patient's age at diagnosis, at time to first or subsequent relapses, as well as potential comorbidities often preclude the use of chemotherapy. Recent progress has been made in our understanding of dysregulated pathways and immunologic antitumor responses in indolent lymphoma. Major therapeutic advances have been achieved in the development of nonchemotherapeutic agents, making "chemo-free" treatment a near-future reality. In this article, we highlight these promising approaches, such as the combination of anti-CD20 antibodies with immunomodulatory drugs, with mAbs directed against other surface antigens such as CD22, with immunomodulatory antibodies such as PD-1, or with inhibitors of key steps in the B-cell receptor pathway signaling. However, the cost of such therapies and potential, albeit manageable, toxicity should be considered. Phase III trials will confirm the benefit of these new treatment strategies that do not require a chemotherapeutic drug and help us identify their exact place in the therapeutic armamentarium for indolent lymphoma. Here we focus on follicular lymphoma, which is the most frequent subtype of indolent lymphoma and for which an increasing body of evidence has emerged that supports the dawn of a new era of chemotherapy-free treatment.
Introduction
A major step forward in the treatment of indolent lymphoma was the development and broad use of a mAb targeting the CD20 antigen on the surface of B cells. One pivotal study and three randomized trials demonstrated a significant, prolonged, progression-free, event-free, or overall survival (PFS, EFS, or OS, respectively) with the use of a rituximab-containing first-line regimen compared with chemotherapy alone (1) (2) (3) (4) (5) .
However, the short-and long-term toxicities of such a chemotherapy-based regimen cannot be underestimated. Short-term toxicity usually includes cytopenias, with increased infectious disease risk, whereas secondary neoplasia (either of solid or hematopoietic types) is the main concern for long-term toxicity (6, 7) . Therefore, new strategies with a chemotherapy-free regimen aimed at precluding such toxicities while providing an equivalent or higher response rate and response duration are eagerly awaited for indolent lymphomas.
In this CCR Focus section, we discuss how anti-CD20 antibodies-alone or in association with other mAbs, with immunomodulatory agents, or with molecules targeting critical signaling pathways ( Fig. 1 )-might replace conventional therapy in the near future, moving us into a new "chemo-free" era. The impact of these therapies on the established "watch and wait" approach for appropriate patients will be a subject for future discussion (see Text Box 1).
Single-Agent Anti-CD20 in Indolent Lymphomas

Rituximab
Rituximab is a monoclonal chimeric antibody ( Fig. 2A ) directed against the CD20 antigen that is expressed on the surface of B-cell lymphomas (Table 1) . It mediates complement and antibody-dependent cell-mediated cytotoxicity (CDC and ADCC, respectively) in addition to exerting a direct antiproliferative and proapoptotic effect (Fig. 2B) . Rituximab displayed an impressive overall response rate (ORR) of 48% in a pivotal study performed by McLaughlin and colleagues (8) in relapsed anti-CD20 na€ ve patients with a history of indolent lymphoma of more than 15 years. One hundred and sixty patients were enrolled from 31 centers and treated with four weekly doses of 375 mg/m 2 of rituximab. The projected median time to progression was 13 months in responders. In the study by Maloney and colleagues (9) , which was a similarly designed phase II trial, single-agent rituximab yielded an ORR of 46%. Importantly, the toxicity was mild and mostly limited to infusion-related reactions (IRR; Table 2 ). Several studies confirmed the potency of the mAb in relapsed or refractory indolent lymphomas (10, 11; Table 1 ). The use of rituximab as a single agent was further evaluated in the first-line setting and similarly produced a high ORR of 70% to 75% with approximately 30% of cases with complete response (CR) and an extended time to treatment failure of 2 years (12-16; Table 1 ).
Maintenance of rituximab after rituximab monotherapy induction has shown interesting results in two randomized studies by the UK Intergroup and the U.S.-based ECOG group (RESORT study) by demonstrating prolonged PFS (17) (18) . However, no consistent benefit in terms of time to next chemotherapy, time to treatment failure, or OS was observed.
Other anti-CD20 antibodies
Given the potency of rituximab, other anti-CD20 antibodies have been developed to increase the CDC, ADCC, or direct toxicity (Fig. 2B) .
Ofatumumab was the first anti-CD20 mAb to be approved in the United States and European Union (EU) for patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. Ofatumumab as monotherapy also demonstrated some efficacy in follicular lymphoma and Waldenstr€ om macroglobulinemia. Ofatumumab was evaluated in 40 refractory/relapsed follicular lymphoma patients in a phase I/II dose-escalation trial and produced a promising 41% ORR across all doses (300, 500, 700, and 1,000 mg) at week 19 and a 60% ORR in the 1,000-mg cohort at week 26 (19) . The antibody was further tested in a phase II study of 116 pretreated patients with follicular lymphoma refractory to previous rituximab therapy and resulted in a modest 11% ORR and a median response duration of 6 months (20) . Ofatumumab was well tolerated in both studies with mainly grade 1/2 IRR at first infusion (Table 2) .
Obinutuzumab is a type II anti-CD20 antibody that results in a lower CDC but in a significantly higher ADCC and direct cell death compared with type I anti-CD20 antibodies (like rituximab and ofatumumab), characterized by their ability to stabilize CD20 on lipid rafts and hence to induce high CDC (21, 22) . Obinutuzumab has been Nonchemotherapeutic agents in the treatment of indolent lymphoma. mAbs can be directed against B-cell surface antigens such as CD20, which is expressed by tumor cells and mediates complement, antibody-dependent cell-mediated cytotoxicity or direct cell death (part 1). Antibodies can also be directed against coreceptors with immunomodulatory functions such as PD-1, which is expressed on antitumor cells (NK or CD8 T cells) and impairs the ligand/ receptor axis to foster an immune response (part 2). The antitumor response might be strengthened by a nonantibody immunomodulatory agent such as lenalidomide as well (part 3). Finally, tumor cell death might also be promoted by targeted agents that impede critical signaling pathways, such as ibrutinib, which impedes BTK, a step in the B-cell receptor (BCR) signaling pathway (part 4). Ag, antigen.
approved recently both in the United States and the European Union in combination with chlorambucil for first-line treatment of patients with CLL. Two phase I studies were conducted in patients with relapsed/refractory CD20 þ nonHodgkin lymphoma with no dose-limiting toxicities and mainly grade 1/2 IRR (23, 24). Notably, rare cases of tumor lysis syndrome and grade 3/4 reactions were observed. The first single-arm phase II studies indicated an appealing benefit of obinutuzumab monotherapy in heavily pretreated patients with indolent non-Hodgkin lymphoma, of whom 55% were rituximab refractory. The final treatment response rate was 55% (with a 11.3 months median PFS) in the higher-dose cohort, with an impressive 50% of ORR in the rituximab-refractory subcohort of patients (25) . A randomized phase II trial comparing head-to-head obinutuzumab with rituximab induction treatment followed by a 2-year maintenance for indolent lymphoma demonstrated a significantly increased ORR for patients receiving obinutuzumab after induction (43% vs. 28% as assessed by a central review), but there was no difference in the PFS (ref. 26 ; Table 1 ). Veltuzumab is a humanized anti-CD20 mAb with a complementary determining region that is identical to rituximab (27) . Phase I/II studies showed excellent tolerability and encouraging response rates in patients with previously treated follicular lymphoma and good bioavailability after delivery either by the intravenous or subcutaneous route (28, 29 ; Tables 1 and 2 ).
At present, rituximab remains the only FDA-and European Medical Agencies approved anti-CD20 mAb for relapsed follicular lymphoma, and in addition to its wide use in combination with chemotherapy, monotherapy is commonly used both in the relapse and first-line setting. Until clinical trials evaluating newer anti-CD20 mAbs (such as those approved in CLL) head to head against rituximab demonstrate equivalence or superiority, it remains hypothetical to foresee their approval as single agents in the near future. However, further development of anti-C20 mAbs in combinations, as discussed below, is under way to increase the rate and durability of responses.
Armed mAbs
Armed antibodies, either as radiolabeled antibodies or as antibody drug conjugates, also play a role in the management of patients with indolent lymphoma. While the latter (still in clinical development) can be viewed as a smarter way to deliver cytotoxic drugs (30) , radioimmunotherapy (RIT) can be considered as one of the chemo-free options already available. Essentially represented by two anti-CD20 radiolabeled antibodies ( 131 I-tositumomab or 90 Y-ibritumomab tiuxetan), RIT has been shown to be one of the most active therapies in indolent lymphoma, providing a high response rate in relapsed/refractory or previously untreated patients (31) . When used as single agents, short-term reversible hematologic toxicities represent the prominent side effect and are easily manageable, whereas long-term toxicities (including the risk of myelodysplastic syndromes) are rare and do not seem to exceed those encountered with chemotherapy regimens (31) . Although anecdotal reports of prolonged responses have appeared, especially in the first-line setting (32) , few pivotal randomized studies have been conducted. When a single infusion of 90 Y-ibritumomab tiuxetan was compared head to head with rituximab (4 weekly infusions), time to progression was not statistically different between the two options, although response duration was much longer with RIT (33) . In summary, RIT still represents a very efficient way to achieve a clinical response in patients with indolent lymphoma, but despite a development started more than 10 years ago, its role in the Text Box 1. Expert opinion: Did "watch and wait" become obsolete with chemo-free options?
Because of the indolent clinical course of follicular lymphoma, its frequent asymptomatic presentation, and considering data obtained in prospective studies having evaluated its safety, watchful waiting has represented a well-validated management option in use for several decades, especially in newly diagnosed patients. One may then ask whether the chemo-free approaches will lead to abandonment of its use. In the first-line setting, despite a significant delayed time to progression, there is still no data indicating that early therapeutic intervention with rituximab (either as a short course or as prolonged treatment) results in short-or long-term improvement of overall survival.
In one randomized trial (17) comparing watchful waiting with rituximab, patients who were allocated after randomization to the watch and wait arm of the study appeared to have presented more anxiety than those treated. However, these results have a certain degree of bias, given patient participation in such a study and the detailed information provided to patients before randomization.
It is, however, true that for some patients, feeling anxious about living with an untreated cancer despite adequate information, or for those who experience asymptomatic (but sometimes palpable) progression, chemo-free approaches represent a valuable option, as long as they are not associated with clinically relevant toxicities. However, all experienced hemato-oncologists recommending watchful waiting do know that a substantial proportion of patients will feel comfortable with simple clinical surveillance and can remain free of therapeutic intervention for years. Likewise, delaying a new intervention in patients who have experienced multiple relapses may also be acceptable.
Of note, with increasing concerns about health care costs, and the rising prices of new drugs, this is a strategy obviously using fewer resources. Hence, until chemofree approaches eventually demonstrate at least an improvement in overall survival in patients with indolent lymphoma, watchful waiting in selected cases should still be considered as one of the management options to be discussed with patients.
current clinical practice has not been firmly established (31, 34) .
Other antibody-based therapy in indolent lymphomas
Successful development of anti-CD20 antibodies prompted the use of other tumor cell surface antigens as the target of mAb (Table 1 and Fig. 3A) .
CD22 is widely expressed on the surface of B cells. Naked humanized CD22 mAb epratuzumab yielded a limited ORR of 18% in recurrent indolent non-Hodgkin lymphoma across all subtype histologies and dose levels (35) . Concurrent administration of rituximab and epratuzumab, used first line for patients with follicular lymphoma, produced an ORR of 88% and CR of 42% as well as a prolonged response duration (60% of patients still in remission after 3 years; ref. 36) .
Other mAbs, such as anti-CD37 (otlertuzumab) or anti-CD74 (milatuzumab) antibodies, are currently in earlyphase development. CD37 is expressed at a high concentration on the surface of B cells. Properly speaking, otlertuzumab is not an mAb; instead, it is an anti-CD37 protein (50) Thrombocytopenia (40) Anemia (40) Diarrhea (30) Leukopenia (30) Neutropenia (50) Thrombocytopenia (20) Leukopenia (10) Anemia (10) Asthenia (5) Pneumonia (5) Other targeted therapies Toxicities in indolent lymphoma were extrapolated from a phase I study in multiple myeloma as no study of the mAb in monotherapy has been published in indolent lymphoma. therapeutic consisting of an IgG1 variable region and a small, engineered constant region, allowing for better tumor penetration. Otlertuzumab was well tolerated but produced modest activity as a single agent in CLL in a recently published phase I study (37) . CD74 is the invariant chain of the MHC class II molecule and is expressed in non-Hodgkin lymphoma. A phase I study evaluated the safety of the anti-CD74 humanized antibody milatuzumab as a single agent in multiple myeloma (38) , and a phase I study showed a safe profile and a 22% ORR in heavily pretreated patients with various non-Hodgkin lymphoma histologies who were treated with an association of milatuzumab and veltuzumab (including indolent and aggressive lymphomas; ref. 39 ).
The anti-CD80 mAb galiximab provided modest results, both as a single agent and in association with rituximab, in follicular lymphoma [72% of ORR with 48% of CR/CRu (unconfirmed CR) in de novo follicular lymphoma], and its development was further placed on hiatus (40) (41) (42) .
Bispecific antibodies, such as blinatumomab (an anti-CD19/anti-CD3 antibody that engage T cells and malignant B cells) or Bs20Â22 (a bispecific antibody against CD20 and CD22 composed of epratuzumab conjugated with 4 Fab regions from veltuzumab), are at the very early stages of development for indolent lymphoma. Blinatumomab has shown promising results albeit with notable toxicity (of the central nervous system; ref. 43) . Preclinical data on Bs20Â22 demonstrated that it has more tumoricidal activity than does the parent antibody alone (44) . Toxicities of those mAb are presented in Table 2 .
It remains to be determined whether or not clinical trials will demonstrate that these new naked antibodies are able to provide a substantial clinical benefit for patients with indolent lymphoma. Until then, they will remain investigational agents in the field.
Vaccine approach
Idiotype vaccination consists in an immunization with the tumor B-cell idiotype (i.e., the unique variable region of the B-cell receptor at the surface of the tumor B cell). In follicular lymphoma, both humoral and cellular immune responses have been observed following idiotype vaccine strategies. However, three phase III trials in follicular lymphoma had disappointing results wherein the primary endpoint was not achieved (45-47) except for one trial with a significant disease-free survival coprimary endpoint as per protocole (47) . An interesting correlation between the immune response against the tumor B-cell idiotype and the PFS was demonstrated in one of these trials (46) .
Immunomodulation in Indolent Lymphoma Treatment
Antibody-based immunomodulation
Most therapeutic mAbs target surface antigens that are expressed on the surface of the tumor cells and mediate CDC or ADCC. However, increasing numbers of antibodies are now also designed to foster the antitumor immune response (Fig. 3B and Table 1 ). Indolent lymphomas are characterized by an important interplay between malignant cells and their microenvironment (48, 49) . PD-L1 (programmed death ligand 1) is highly expressed by histiocytes within the T-cell-rich zone of the tumor follicles and is thought to play a crucial role in T-cell exhaustion (50, 51) . The programmed cell-death 1 (PD-1)-PD-L1/2 axis was considered an attractive target, and disrupting this axis by anti-PD-1-blocking antibodies has produced promising results. Westin and colleagues (52) recently published the results of a phase II study on pidilizumab, an anti-PD1 antibody, combined with rituximab in relapsed follicular lymphoma. The combination provided a high ORR of 66% (19 of 29 patients) and CR rate of 52% (15 of 29) with a median PFS of 18.8 months. Other anti-PD1-blocking antibodies, such as nivolumab or lambrolizumab (MK-3475), which demonstrated encouraging activity in melanoma, are currently under scrutiny for the treatment of indolent lymphoma (clinicaltrials.gov identifiers: NCT02038946 and NCT01953692).
Although no trials have either been published or are currently recruiting for evaluating the other immunomodulatory axes, blocking or agonistic antibodies that modify the interaction of receptors, such as CD47, CD137, or killer immunoglobulin-like receptor (KIR), with their ligands are emerging as promising tools in the treatment of indolent lymphoma (Table 1) . CD47 is highly expressed on nonHodgkin lymphoma tumor cells and inhibits phagocytosis through activation of signal regulatory protein a expressed on the surface of macrophages and dendritic cells. The combination of the blocking anti-CD47 antibody and rituximab was shown to increase Fc receptor (FcR)-dependent and -independent stimulation of phagocytosis and prolonged survival of mice transplanted with human lymphoma cell lines (53) . Anti-CD47 antibody has been tested as a single agent in a phase I dose-escalating study for advanced or metastatic solid tumors, but it has not yet been used to treat hematologic malignancies. CD137 is expressed and upregulated by natural killer (NK) cells upon binding the anti-CD20-covered non-Hodgkin lymphoma cells during activation. Agonistic anti-CD137 antibodies stimulate NK cells that have been activated by a tumor-specific mAb, resulting in increased ADCC (54) (55) (56) (57) . Trials evaluating anti-CD137 have been completed in solid tumors, but studies in indolent non-Hodgkin lymphoma in combination with rituximab are still needed. Similarly, MHC class I antigens expressed on the surface of lymphoma cells decrease NK cell antitumoral response via their interaction with KIR. Therefore, immunomodulation with blocking anti-KIR antibodies aimed at fostering the NK cell antitumor response is currently under development. Trials in myeloma, acute leukemia, or solid tumors with anti-KIR antibody (lirilumab) are ongoing, and preclinical models in lymphoma show encouraging results (58) .
Immunomodulatory drugs in indolent lymphoma
First successfully used in multiple myeloma, immunomodulatory drugs (IMiD) such as lenalidomide have now entered the armamentarium against indolent lymphomas (Table 1 and Fig. 3B ). Whereas somewhat disappointing results in indolent lymphoma were observed with the use of thalidomide as a single agent (59, 60) , encouraging response rates were observed with lenalidomide. A defect in the ability of tumor-infiltrating T cells to form an immune synapse with tumor cells was demonstrated in patients with follicular lymphoma, and this defect was reversed by treatment with the IMiD lenalidomide (61) .
A pilot phase II trial was conducted in relapsed/refractory indolent non-Hodgkin lymphoma with lenalidomide. This treatment yielded a moderate ORR of 23% with a 7% CR or CRu but a prolonged response duration (RD) among responders (median RD was at least 16.5 months; ref. 62) . As expected, grade 3/4 adverse events included neutropenia and thrombocytopenia. Encouraging results with lenalidomide prompted several cooperative groups worldwide to use the drug in combination with chemotherapy (which is beyond the spectrum of this review) and/or rituximab. Three phase II studies confirmed the efficacy of lenalidomide when used with rituximab in relapsed and refractory patients with an ORR ranging from 49% to 86%, except in grade 3 follicular lymphoma cases in which only a 25% response was observed (63) (64) (65) . Preliminary results from a randomized study comparing lenalidomide alone or in combination with rituximab demonstrated a clear benefit of the combination with an ORR of 75% and 32% CR/CRu compared with 49% and 13%, respectively, with the use of lenalidomide as a single agent. The EFS was also significantly prolonged in the combination treatment arm (2.0 vs. 1.2 years, P ¼ 0.0063; ref. 66) .
In de novo indolent lymphoma, a phase II study assessed the safety and efficacy of lenalidomide and rituximab for 110 patients with advanced-stage disease and various histologies [small lymphocytic lymphoma (SLL), n ¼ 30; follicular lymphoma, n ¼ 50; marginal zone lymphoma, n ¼ 30]. The ORR for evaluable patients was 90% for all patients and an impressive 98% in follicular lymphoma (87% CR/CRu). As an indicator of the depth of response, nearly all patients with follicular lymphoma experienced a molecular response, as assessed by PCR, at the end of therapy (6 courses of a 28-day cycle) and 93% achieved a metabolic response, as assessed by PET scanning (42 of 45 with an initial PET scan evaluation; ref. 67) .
To confirm these excellent results with a chemo-free regimen combining lenalidomide and rituximab, two randomized trials are currently ongoing. The trial from the Swiss and Nordic lymphoma groups (clinicaltrials.gov identifier: NCT01307605) enrolled patients with advancedstage follicular lymphoma in need of therapy. This trial compared four courses of weekly rituximab at weeks 1, 2, 3, and 4 followed by four more weekly infusions (in case of a response at week 10) at weeks 12, 13, 14, and 15 with the same regimen in combination with lenalidomide at a 15-mg dose without interruption. A study conducted by the Lymphoma Study Association group and U.S. investigators (clinicaltrials.gov identifier: NCT01650701) aims to compare an immunotherapy-based induction regimen followed by a 2-year rituximab maintenance dosing as designed in the PRIMA trial (experimental arm of treatment; ref. 68 ) with a lenalidomide plus rituximab regimen (induction and maintenance).
However, the long-term safety profile of lenalidomide use must be carefully followed given concerns about secondary malignancies that have emerged in patients with multiple myeloma, but particularly when lenalidomide is used in association with alkylating agents such as melphalan ( Targeted Therapy Other than mAbs
BTK and PI3K inhibitors
Ibrutinib (formerly PCI-32765), a first-in-human Bruton's tyrosine kinase (BTK) inhibitor, was specified as a "breakthrough therapy" by the FDA in 2013 (Fig. 3C) . It displayed impressive preclinical activity both in vitro and in vivo in animal models (70) , and already achieved FDA and EMA approval for mantle cell lymphoma and CLL. A phase I trial evaluated escalating doses of ibrutinib without reaching an MTD. Six of 16 patients with follicular lymphoma, 3 of 4 with Waldenst€ om macroglobulinemia, and 1 of 4 with mantle cell lymphoma achieved a clinical response (71) . The FLR2002 study a phase II single-arm study of ibrutinib, aims to enroll 110 patients with relapsed/refractory follicular lymphoma and is ongoing (clinicaltrial.gov identifier NCT01779791; ref. 72) . Other trials testing ibrutinib in combination with rituximab (clinicaltrial.gov identifier NCT01980654) and lenalidomide (clinicaltrial.gov identifier NCT01829568) are currently accruing (Table 1) .
Idelalisib (formerly CAL-101 or GS-1101), a PI3K d inhibitor (Fig. 3C) , was recently approved by the U.S. and European Union drug agencies for CLL (in combination with rituximab) and for follicular lymphoma. In a phase I study, idelalisib showed no major toxicity with an encouraging 47% response rate in patients with indolent lymphoma (73) . Full FDA approval in CLL was based on a randomized trial in combination with rituximab versus rituximab with placebo, whereas in follicular lymphoma, accelerated approval was based on a phase II single-arm, openlabel study. Among the 125 patients (follicular lymphoma, n ¼ 72; SLL, n ¼ 28; Waldenst€ om macroglobulinemia, n ¼ 10; mantle zone lymphoma, n ¼ 13) enrolled, the ORR was 57% with a CR rate of 6%, the median duration of response was 12.5 months, and the median PFS was 11 months (74). Other PI3K inhibitors and combinations of idelalisib with other agents (clinicaltrial.gov identifier NCT01732913), including rituximab, are under investigation (Table 1) .
Although ibrutinib and idelalisib are well tolerated (Table 2) , no long-term follow-up is currently available.
Other agents
Proteasome inhibitors, such as bortezomib, provided encouraging results as a monotherapy (75) (76) (77) Chemotherapy-Free Approaches in Indolent Lymphoma play a role in the activity. Although the PFS was significantly prolonged in combination with rituximab in a phase III randomized trial for relapsed rituximab-na€ ve or rituximabsensitive patients with follicular lymphoma (P ¼ 0.038), the limited median PFS improvement (12.8 months vs. 11 months) was considered as being clinically irrelevant in this chronic disease (79; Table 1 ). Data on the preclinical efficacy and clinical safety of carfilzomib in lymphoma are emerging (80, 81) . Emerging preliminary clinical data with the bcl-2 inhibitor ABT/GDC-199 showed 28% of response in 13 patients with follicular lymphoma, 75% in 4 patients with Waldenst€ om macroglobulinemia, and 67% in 3 patients with marginal zone lymphoma, respectively (82) . This compound will be rapidly evaluated, as a single agent or in combination, further expanding the chemo-free approaches in indolent lymphoma.
Conclusions
In a matter of only a few years, targeted therapies have changed the landscape for lymphoma treatment in general and indolent lymphoma treatment in particular. A brief overview of such treatments is presented in this review, whereas new directions in other lymphoma subtypes are presented in this edition of CCR Focus (83) (84) (85) (86) (87) . Among other promising approaches, combining anti-CD20 antibodies with IMiDs, mAbs directed against other surface antigens such as CD22, immunomodulatory antibodies such as PD-1, or inhibitors of the B-cell receptor (BCR) pathway is of paramount interest. Among inhibitors of the BCR pathway, PI3K inhibitors such as idelalisib might rapidly be a key treatment of indolent lymphoma due to its high potency and favorable toxicity profile.
Off-target effects of such therapies must not be underestimated. Chemo-free treatments are not "toxicity-free" treatments, and significant side effects might be IRR with mAbs, cytopenias with lenalidomide, or cytolytic hepatiti and diarrhea or pneumonitis with idelalisib. Furthermore, no sufficient long-term follow-up has been provided to fully address the question of detrimental side effects such as secondary neoplasia. The benefit-cost ratio of such therapies will have also to be fully appraised because the price of those new agents is high.
With the use of rituximab as a single agent in routine practice for selected patients, we have already entered the era of chemo-free regimens for the management of patients with indolent lymphoma. However, at least for high-tumor burden follicular lymphoma, nodal and extra-nodal mantle zone lymphoma, Waldenst€ om macroglobulinemia, or SLL, immunochemotherapy-based treatments are still the standard of care for first-line treatment, and chemo-free regimens cannot be recommended outside of clinical trials. It is of utmost importance for the design of these studies enable us to evaluate the true clinical benefit of these agents and their long-term safety, to allow the regulatory approval of the new agents and establish their use in therapeutic algorithms for clinical practice.
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